Systematic Financial Management LP Acquires 248,817 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Systematic Financial Management LP lifted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 40.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 860,563 shares of the life sciences company's stock after purchasing an additional 248,817 shares during the quarter. Systematic Financial Management LP owned 1.12% of Integra LifeSciences worth $19,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Arrowstreet Capital Limited Partnership raised its stake in shares of Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares during the last quarter. Quadrant Capital Group LLC increased its position in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Sterling Capital Management LLC increased its position in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the last quarter. Finally, Covestor Ltd increased its position in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

IART has been the subject of a number of research reports. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. JPMorgan Chase & Co. reduced their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, JMP Securities reduced their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Price Performance

Shares of NASDAQ IART traded down $0.08 during mid-day trading on Thursday, reaching $12.61. The company's stock had a trading volume of 609,682 shares, compared to its average volume of 1,041,027. The firm has a market capitalization of $979.95 million, a PE ratio of -139.98, a P/E/G ratio of 0.73 and a beta of 1.27. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a fifty day moving average of $17.45 and a two-hundred day moving average of $21.54. Integra LifeSciences Holdings Co. has a 52 week low of $11.60 and a 52 week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business's revenue was up 3.7% on a year-over-year basis. During the same period last year, the company earned $0.55 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.